Literature DB >> 33058848

Testosterone, dihydrotestosterone, bone density, and hip fracture risk among older men: The Cardiovascular Health Study.

Emily A Rosenberg1, Petra Bůžková2, Howard A Fink3, John A Robbins4, Molly M Shores5, Alvin M Matsumoto6, Kenneth J Mukamal7.   

Abstract

BACKGROUND: Little is known about the relationships of dihydrotestosterone (DHT), a more potent androgen than testosterone (T), with bone mineral density (BMD) and fracture risk. Our objectives were to evaluate the relationships of T, DHT and sex hormone binding globulin (SHBG) with BMD, fracture risk, and lean body mass (LBM).
METHODS: We evaluated 1128 older men free of cardiovascular disease in a prospective cohort study using data from the Cardiovascular Health Study. T and DHT were measured by liquid chromatography-tandem mass spectrometry and SHBG by fluoroimmunoassay. Our outcomes included incident hip fracture (n = 106) over a median of 10.2 years and BMD and LBM by dual-energy x-ray absorptiometry (n = 439).
RESULTS: In Cox regression models mutually adjusted for T, SHBG, and covariates, each standard deviation increment in DHT (0.23 ng/ml) was associated with a 26% lower risk of hip fracture (adjusted hazard ratio [aHR] 0.74, 95% confidence interval (CI) 0.55-1.00, p = 0.049). Similarly, SHBG was associated with fracture in mutually adjusted models (aHR HR 1.26, 95% CI, 1.01-1.58, p = 0.045). In contrast, T (aHR, 1.16, 95% CI, 0.86-1.56, p = 0.324) was not significantly associated with fracture in mutually adjusted models. T, DHT and SHBG were not associated with BMD. T and DHT were both positively associated with LBM in individual models.
CONCLUSIONS: In older men, DHT was inversely associated with hip fracture risk and SHBG was positively associated with hip fracture risk, while T was not. Future studies should elucidate the mechanisms by which DHT affects bone health.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Androgen; Bone mineral density; Dihydrotestosterone; Hip fracture; Testosterone

Mesh:

Substances:

Year:  2020        PMID: 33058848      PMCID: PMC9060596          DOI: 10.1016/j.metabol.2020.154399

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   13.934


  43 in total

1.  Body mass index is not a good predictor of bone density: results from WHI, CHS, and EPIDOS.

Authors:  John Robbins; Anne-Marie Schott; Rahman Azari; Richard Kronmal
Journal:  J Clin Densitom       Date:  2006-05-02       Impact factor: 2.617

2.  The reliability of medication inventory methods compared to serum levels of cardiovascular drugs in the elderly.

Authors:  N L Smith; B M Psaty; S R Heckbert; R P Tracy; E S Cornell
Journal:  J Clin Epidemiol       Date:  1999-02       Impact factor: 6.437

3.  Dihydrotestosterone is a determinant of calcaneal bone mineral density in men.

Authors:  Ramachandran Ilangovan; Sivanandane Sittadjody; Muthusamy Balaganesh; Ramadoss Sivakumar; Bhaskaran Ravi Sankar; Karundevi Balasubramanian; Subramanian Srinivasan; Chinappa Subramanian; David M Thompson; Lurdes Queimado; Narasimhan Srinivasan
Journal:  J Steroid Biochem Mol Biol       Date:  2009-09-02       Impact factor: 4.292

4.  Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study.

Authors:  S Amin; Y Zhang; C T Sawin; S R Evans; M T Hannan; D P Kiel; P W Wilson; D T Felson
Journal:  Ann Intern Med       Date:  2000-12-19       Impact factor: 25.391

5.  Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.

Authors:  D M Huber; A C Bendixen; P Pathrose; S Srivastava; K M Dienger; N K Shevde; J W Pike
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

Review 6.  Epidemiology and outcomes of osteoporotic fractures.

Authors:  Steven R Cummings; L Joseph Melton
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

Review 7.  The validity of administrative data to identify hip fractures is high--a systematic review.

Authors:  Marie Hudson; Antonio Avina-Zubieta; Diane Lacaille; Sasha Bernatsky; Lisa Lix; Sonia Jean
Journal:  J Clin Epidemiol       Date:  2013-03       Impact factor: 6.437

8.  Association between 5-alpha reductase inhibition and risk of hip fracture.

Authors:  Steven J Jacobsen; T Craig Cheetham; Reina Haque; Jiaxiao M Shi; Ronald K Loo
Journal:  JAMA       Date:  2008-10-08       Impact factor: 56.272

9.  Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study.

Authors:  Molly M Shores; Mary L Biggs; Alice M Arnold; Nicholas L Smith; W T Longstreth; Jorge R Kizer; Calvin H Hirsch; Anne R Cappola; Alvin M Matsumoto
Journal:  J Clin Endocrinol Metab       Date:  2014-03-14       Impact factor: 5.958

10.  Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study.

Authors:  Molly M Shores; Alice M Arnold; Mary L Biggs; W T Longstreth; Nicholas L Smith; Jorge R Kizer; Anne R Cappola; Calvin H Hirsch; Brett T Marck; Alvin M Matsumoto
Journal:  Clin Endocrinol (Oxf)       Date:  2014-05-05       Impact factor: 3.478

View more
  2 in total

Review 1.  Bone health in ageing men.

Authors:  Karel David; Nick Narinx; Leen Antonio; Pieter Evenepoel; Frank Claessens; Brigitte Decallonne; Dirk Vanderschueren
Journal:  Rev Endocr Metab Disord       Date:  2022-07-16       Impact factor: 9.306

Review 2.  Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge.

Authors:  Matti L Gild; Mark Stuart; Roderick J Clifton-Bligh; Audrey Kinahan; David J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.